Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder

Viela Bio
Published on : Published by : Chris Frew

Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder Designation based on positive primary analysis of pivotal study, N-MOmentum Gaithersburg, MD—April 18, 2019 – Viela Bio today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the Company’s anti-CD19 monoclonal antibody [….]

Leadiant Shows Rare Dedication to Patients With Recent FDA Approval of Revcovi™

Published on : Published by : Steven Surdez

Leadiant Shows Rare Dedication to Patients With Recent FDA Approval of Revcovi™ November 20, 2018 Leadiant Biosciences, Inc. formerly known as Sigma-Tau Pharmaceuticals, recently received FDA approval for Revcovi™, which provides improved treatment for patients living with ADA-SCID, better known as “Bubble Boy Disease.” The journey that lead to Revcovi is a prime example of [….]